HomeAI · summaries
Storia in 3 fonti
Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PIK3α inhibitor’s R&D prospects beyond breast cancer.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Relay drug shows early promise against rare blood vessel diseases
While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available…
- ·
endpoints.news
Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PIK3α inhibitor’s R&D prospects beyond breast cancer.
